1
|
Zhang Y, Wang J, Zhao J, Huang G, Liu K, Pan W, Sun L, Li J, Xu W, He C, Zhang Y, Li S, Zhang H, Zhu J, He Y. Current status and challenges in prenatal and neonatal screening, diagnosis, and management of congenital heart disease in China. THE LANCET. CHILD & ADOLESCENT HEALTH 2023; 7:479-489. [PMID: 37301215 DOI: 10.1016/s2352-4642(23)00051-2] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2022] [Revised: 02/24/2023] [Accepted: 02/28/2023] [Indexed: 06/12/2023]
Abstract
Congenital heart disease (CHD), a wide spectrum of diseases with varied outcomes, is the most common congenital malformation worldwide. In this Series of three papers, we describe the burden of CHD in China; the development of screening, diagnosis, treatment, and follow-up strategies; and challenges associated with the disease. We also propose solutions and recommendations for policies and actions to improve the outcomes of CHD. In the first paper in this Series, we focus on prenatal and neonatal screening, diagnosis, and management of CHD. Based on advanced international knowledge, the Chinese Government has developed a network system comprising prenatal screening, diagnosis of CHD subtypes, specialist consultation appointments, and treatment centres for CHD. A new professional discipline, fetal cardiology, has been formed and rapidly developed. Consequently, the overall coverage of prenatal and neonatal screening and the accuracy of CHD diagnoses have gradually improved, and the neonatal CHD mortality rate has decreased substantially. However, China still faces several challenges in the prevention and treatment of CHD, such as insufficient diagnostic capabilities and unqualified consultation services in some regions and rural areas. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
Collapse
Affiliation(s)
- Yingying Zhang
- Maternal-Fetal Medicine Centre in Fetal Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Key Laboratory of Maternal-Fetal Medicine in Fetal Heart Disease, Beijing, China; Beijing Laboratory for Cardiovascular Precision Medicine, Beijing, China; School of Biological Science and Medical Engineering, Beihang University, Beijing, China
| | - Jingyi Wang
- Maternal-Fetal Medicine Centre in Fetal Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Key Laboratory of Maternal-Fetal Medicine in Fetal Heart Disease, Beijing, China; Beijing Laboratory for Cardiovascular Precision Medicine, Beijing, China
| | - Jianxin Zhao
- National Office for Maternal and Child Health Surveillance of China, National Centre for Birth Defect Surveillance of China, West China Second University Hospital, Sichuan University, Chengdu, China
| | - Guoying Huang
- Pediatric Heart Centre, Children's Hospital of Fudan University, Shanghai, China
| | - Kaibo Liu
- Department of Perinatal Health, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China; Department of Perinatal Health, Beijing Maternal and Child Health Care Hospital, Beijing, China
| | - Wei Pan
- Department of Maternal-Fetal Cardiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong Cardiovascular Institute, Guangzhou, China
| | - Luming Sun
- Department of Fetal Medicine & Prenatal Diagnosis Centre, Shanghai Key Laboratory of Maternal-Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China
| | - Jun Li
- Department of Ultrasound, Xijing Hospital, Xi'an, China
| | - Wenli Xu
- National Office for Maternal and Child Health Surveillance of China, National Centre for Birth Defect Surveillance of China, West China Second University Hospital, Sichuan University, Chengdu, China
| | - Chunhua He
- National Office for Maternal and Child Health Surveillance of China, National Centre for Birth Defect Surveillance of China, West China Second University Hospital, Sichuan University, Chengdu, China
| | - Yunting Zhang
- Child Health Advocacy Institute, Shanghai Children's Medical Center, National Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Shoujun Li
- Pediatric Cardiac Surgery Center and State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
| | - Hao Zhang
- Heart Center and Shanghai Institute of Pediatric Congenital Heart Disease and Shanghai Clinical Research Center for Rare Pediatric Diseases, Shanghai Children's Medical Center, National Children's Medical Center, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Jun Zhu
- National Office for Maternal and Child Health Surveillance of China, National Centre for Birth Defect Surveillance of China, West China Second University Hospital, Sichuan University, Chengdu, China; Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, and Sichuan Birth Defects Clinical Research Centre, West China Second University Hospital, Sichuan University, Chengdu, China
| | - Yihua He
- Maternal-Fetal Medicine Centre in Fetal Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Key Laboratory of Maternal-Fetal Medicine in Fetal Heart Disease, Beijing, China; Beijing Laboratory for Cardiovascular Precision Medicine, Beijing, China.
| |
Collapse
|
5
|
Hu K, Wan Y, Lee FT, Chen J, Wang H, Qu H, Chen T, Lu W, Jiang Z, Gao L, Ji X, Sun L, Xiang D. Functional Analysis of an Intronic FBN1 Pathogenic Gene Variant in a Family With Marfan Syndrome. Front Genet 2022; 13:857095. [PMID: 35547258 PMCID: PMC9081721 DOI: 10.3389/fgene.2022.857095] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2022] [Accepted: 03/07/2022] [Indexed: 01/16/2023] Open
Abstract
Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder that canonically affects the ocular, skeletal, and cardiovascular system, in which aortic tear and rupture is the leading cause of death for MFS patients. Genetically, MFS is primarily associated with fibrillin-1 (FBN1) pathogenic variants. However, the disease-causing variant in approximately 10% of patients cannot be identified, partly due to some cryptic mutations that may be missed using routine exonic sequencing, such as non-coding intronic variants that affects the RNA splicing process. We present a 32-year female with typical MFS systemic presentation that reached to a clinical diagnosis according to the revised Ghent nosology. We performed whole-exome sequencing (WES) but the report failed to identify known causal variants when analyzing the exonic sequence. However, further investigation on the exon/intron boundaries of the WES report revealed a candidate intronic variant of the fibrillin 1 (FBN1) gene (c.248-3 C>G) that predicted to affect the RNA splicing process. We conducted minigene splicing analyses and demonstrated that the c.248-3 C>G variant abolished the canonical splicing site of intron 3, leading to activation of two cryptic splicing sites and causing insertion (c.248-1_248-2insAG and c.248-1_248-282ins). Our study not only characterizes an intronic variant to the mutational spectrum of the FBN1 gene in MFS and its aberrant effect on splicing, but highlights the importance to not neglect the exon/intron boundaries when reporting and assessing WES results. We point out the need of conducting functional analysis to verify the pathogenicity of intronic mutation, and the opportunity to re-consider the standard diagnostic approaches in cases of clinically diagnosed MFS with normal or variant of unknown significance genetic results.
Collapse
Affiliation(s)
- Kui Hu
- Department of Cardiovascular Surgery, Guizhou Provincial People's Hospital, Guiyang, China
| | - Yun Wan
- Department of Endocrinology, Guizhou Provincial People's Hospital, Guiyang, China
| | - Fu-Tsuen Lee
- Department of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.,Division of Cardiology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
| | - Jinmiao Chen
- Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
| | - Hao Wang
- Institute of Precision Medicine, The Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Haonan Qu
- Department of Thoracic and Cardiovascular Surgery, The Third People's Hospital of Mianyang City, Mianyang, China
| | - Tao Chen
- Department of Cardiovascular Surgery, Guizhou Provincial People's Hospital, Guiyang, China
| | - Wang Lu
- Department of Cardiovascular Surgery, Guizhou Provincial People's Hospital, Guiyang, China
| | - Zhenwei Jiang
- Department of Cardiovascular Surgery, Guizhou Provincial People's Hospital, Guiyang, China
| | - Lufang Gao
- Department of Cardiovascular Surgery, Guizhou Provincial People's Hospital, Guiyang, China
| | - Xiaojuan Ji
- Department of Ultrasound, Chongqing General Hospital, University of Chinese Academy of Sciences, Chongqing, China
| | - Liqun Sun
- Division of Cardiology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
| | - Daokang Xiang
- Department of Cardiovascular Surgery, Guizhou Provincial People's Hospital, Guiyang, China
| |
Collapse
|